Navigation Links
Cellular target may prove useful in treating deadly brain tumors
Date:4/3/2009

DURHAM, N.C. Duke University researchers have identified a receptor on the surface of cells that may give them another avenue of attack against glioblastoma, the most common and most deadly type of brain cancer.

The neurokinin 1 receptor (NK1R), which may be expressed in all human glioblastoma cells, may prove to be an appropriate target for therapies aimed at treating these brain tumors, according to a study led by researchers in the Duke Department of Anesthesiology and the Preston Robert Tisch Brain Tumor Center at Duke.

"There are some previously identified cellular targets for therapy which are now being investigated in clinical trials, and the findings from our research represent potential alternate or complementary targets that may help patients facing this devastating disease," said Madan Kwatra, PhD, a researcher in Duke's department of anesthesiology, and senior investigator on this study. "Patients generally die from the disease within 18 months of glioblastoma diagnosis."

The results of the study were published in the March 30, 2009 online edition of the Journal of Neurochemistry. The study was funded by the National Institutes of Health.

The researchers examined stimulation of the receptor NK1R in human glioblastoma cells growing in a dish, and found that activation of NK1R led to the activation of Akt, a cellular protein that suppresses the natural cell death process.

"In human cancers, this would translate into a proliferation of cancer cell growth," said Kwatra.

The researchers also showed that blocking NK1R activity reduced Akt activity, which then led to greater cell death.

"This finding suggests that if we are able to block NK1R activity, we may have a better shot at stalling cancer growth," Kwatra said.

A previous study showed NK1R activity in 10 out of 10 glioblastomas and nine out of 12 astrocytomas, a lower-grade malignant brain tumor.

Current therapies to treat glioblastomas are directed toward blocking the activity of another cellular receptor called epithelial growth factor receptor (EGFR). A recent clinical trial using an EGFR inhibitor found that patients whose tumors expressed high levels of phosphorylated or chemically altered Akt did not respond to treatment, Kwatra said.

"This underscores the importance of discovering the origin of active Akt in glioblastomas," he said. "We propose that the elevated levels of phosphorylated Akt may come from active forms of NK1R, and it's possible that a better response might be obtained by simultaneously blocking EGFR and NK1R."

Future studies may examine the role of a NK1R inhibitor in glioblastoma patients, perhaps as a corollary to treatment with an EGFR blocker such as erlotinib, which is currently being studied in clinical trials.

"The FDA has already approved a drug for combating chemotherapy-induced nausea and vomiting that happens to be an NK1R inhibitor, so that might be a possibility for study in conjunction with erlotinib," Kwatra said.


'/>"/>

Contact: Lauren Shaftel Williams
lauren.shaftel@duke.edu
919-684-4966
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Herpes: Scientists find cellular process that fights virus
2. Liver cell adenoma or hepatocellular carcinoma?
3. American TeleCare to Present its Wireless Wide Area Network (WWAN) Option for Cellular Telehealth Connectivity at the American Telemedicine Association (ATA) Annual Meeting
4. Seahorse XF96 Extracellular Flux Analyzer Wins Best New Product Award for DRUG DISCOVERY at 2009 Molecular Medicine Conference
5. CompuCyte Corporation and Program in Cellular and Molecular Medicine at Childrens Hospital Boston Announce Joint Program for Quantitative Imaging Cytometry Research Services
6. Enhanced skin cancer risk linked to defects in cellular aging controls
7. Team learns how cellular protein detects viruses and sparks immune response
8. U.S. Cellular President and CEO to Give Keynote at Employment Expo
9. Novel Photoconductive Cellular Depolarization Technology Reveals Insight Into Neuronal Growth, Guidance, and Regeneration
10. CORD:USE Cord Blood Bank Receives Prestigious Accreditation from the Foundation for the Accreditation of Cellular Therapy
11. Dormant cancer cells rely on cellular self-cannibalization to survive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... millions of older Americans at risk of price gouging for their prescription drugs, ... League (TSCL) . “Because Medicare isn’t negotiating on our behalf, there’s no consistency ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Finn Mouseson”: follows the exciting story ... average life. This mouse sets out on a journey that will show that friends ... the creation of newly published author and illustrator, Melody Gersonde-Mickelson, who has earned a ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Financial Favor of God; Second Edition”: a ... Second Edition” is the creation of published author, Brooks Rathell. , “We typically hear ... to you about the financial favor of God. Not only does it exist, but ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... the addition of strategic marketing leader, Denise Flannery, to its strategic advisory and ... and Management Consultant, Denise will work with clients across different industries to develop ...
(Date:9/19/2017)... Dallas, TX (PRWEB) , ... September 19, 2017 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – will return to Texas as a part of its national Swirl: ...
Breaking Medicine News(10 mins):
(Date:9/13/2017)... OrthoAtlanta has been named the official orthopedic and sports ... the 2018 College Football Playoff (CFP) National Championship to be ... Atlanta, Georgia . OrthoAtlanta is proud to ... in many activities leading up to, and including the national ... OrthoAtlanta ...
(Date:9/12/2017)... Sept. 12, 2017  Consumer reviews on the independent review site ... the number one company for hearing aids, ranking it higher than ... brands. ... #1 by Consumers For Hearing Aids ... Hearing is an online store that provides high performance, state-of-the-art, German-engineered ...
(Date:9/9/2017)... 8, 2017 ... Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, September 18 th .The ... free MRI brain scans to the public.Where:  BTF,s ... at 501 K Street NW, Washington, D.C.What:BTF brings its nationwide initiative, the ...
Breaking Medicine Technology: